Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CCB International To Set Up First Health Care Industry Fund With RMB 5 Billion

This article was originally published in PharmAsia News

Executive Summary

CCB International, a wholly-owned subsidiary of China Construction Bank Corporation, recently revealed that it has been establishing a health care investment fund since November 2007. With a first phase investment not exceeding RMB 5 billion, the Tianjin-registered fund will be China's first private equity focusing on the health care industry, including pharmaceuticals, medical devices, medical institutions and health care services. The seven-year closed-end fund obtains capital from various undisclosed sources. CCB International will collaborate with well-known domestic and overseas health care management funds and groups to jointly manage the fund. According to survey, China has a total of 5,744 health care management organizations covering 23 provinces, four municipalities and four autonomous regions. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel